RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Valeant Pharmaceuticals International

A collection of news and information related to Valeant Pharmaceuticals International published by this site and its partners.

Top Valeant Pharmaceuticals International Articles see all

Displaying items 1-5
  • Pharmaceutical giant Actavis plans to rename itself Allergan

    Pharmaceutical giant Actavis plans to rename itself Allergan
    Irish pharmaceutical company Actavis said it will adopt the Allergan name after closing a deal to buy the Irvine Botox maker.
  • Allergan sets up meeting to seek shareholder OK of Actavis acquisition

    Allergan Inc., the Irvine company that makes Botox, scheduled a March 10 special meeting to seek shareholder approval of its acquisition by Irish firm Actavis. Actavis agreed in November to pay about $66 billion in cash and stock to acquire Allergan,...

    Few Allergan execs to keep top jobs in Actavis takeover

    Few Allergan execs to keep top jobs in Actavis takeover
    The soon-to-be owner of Irvine-based Allergan Inc. announced sweeping leadership changes that pass over many current executives including the Botox maker's CEO. Irish pharmaceutical giant Actavis expects to finalize its $66-billion acquisition in the...

    Lawsuit accuses Ackman, Valeant of insider trading in Allergan stock

    Lawsuit accuses Ackman, Valeant of insider trading in Allergan stock
    A new lawsuit accuses hedge fund manager Bill Ackman and Canadian firm Valeant Pharmaceuticals International Inc. of insider trading in Allergan Inc. stock before their unsuccessful bid to acquire the Botox maker. The lawsuit was filed Wednesday on...

    Botox maker Allergan is said to be edging closer to a sale to Actavis

    Botox maker Allergan Inc. is closing in on a deal to be acquired by Irish company Actavis, a move that would potentially thwart a hostile takeover by Canadian company Valeant Pharmaceuticals International Inc. A $62.5-billion deal could be announced...